Jesús San Miguel
Clínica Universidad de Navarra (Pamplona) · Clinica Universidad de Navarra, Universidad de Navarra · Clínica Universitaria de Navarra
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jesús San Miguel as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:28 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07045909 · Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)PETHEMA Foundation · recruiting · De Novo Multiple Myeloma, Anitocabtagene Autoleucel · study director
- Ph2NCT05849610 · Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple MyelomaPETHEMA Foundation · active not recruiting · High-Risk de Novo Multiple Myeloma · study chair
- Ph3NCT05558319 · NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-IberdomidePETHEMA Foundation · recruiting · Newly Diagnosed Multiple Myeloma · study chair
- Ph2NCT05527340 · Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.PETHEMA Foundation · active not recruiting · Multiple Myeloma · study chair
- N/ANCT05218603 · Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCTPETHEMA Foundation · unknown · Multiple Myeloma, Non-eligible for Autologous Stem Cell Transplantation (ASCT) · principal investigator
- Ph1/Ph2NCT05060627 · Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to LenalidomidePETHEMA Foundation · active not recruiting · Relapsed Multiple Myeloma · study chair
- Ph2NCT01325896 · Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · unknown · Multiple Mieloma · principal investigator
- Ph3NCT00480363 · QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of ProgressionPETHEMA Foundation · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:28 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- 670 citationsRCR 18.7
- 575 citationsRCR 12.5
- 414 citationsRCR 8.6
- 239 citationsRCR 5.9
- 151 citationsRCR 4.2
- 48 citationsRCR 1.2
- Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial.Bone Marrow Transplant · 200433 citationsRCR 0.8
- Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.Haematologica · 202429 citationsRCR 3.2
- 25 citationsRCR 0.9
- Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.Haematologica · 201815 citationsRCR 0.5